Group 1 - The core viewpoint of the article highlights the significant stock price increase of Brainstorm Aurora (06681), which rose over 50% to reach a new high of 9.47 HKD following its inclusion in the Hong Kong Stock Connect program effective September 8, 2025 [1] - As of the report, the stock was trading at 8.52 HKD with a trading volume of 579 million HKD, reflecting strong market interest [1] - The company reported a revenue of 100 million HKD for the first half of 2025, representing a year-on-year increase of 92.82% [1] Group 2 - The company has made significant advancements in its core pipeline in research and clinical trials, achieving commercialization for eight indications across four major types of cognitive disorders [1] - Additionally, the company is actively developing treatments for other cognitive disorder indications [1] - The company is pushing for innovation and application of AI in the medical field, having developed a proprietary medical large model, BrainAuGPT, which received a national invention patent for its novel training task combination method based on GBR second-order knowledge representation [1]

Core Viewpoint - Brain动极光 (06681) has seen a significant stock price increase of over 50%, reaching a new high of 9.47 HKD following its inclusion in the Hong Kong Stock Connect program, effective September 8, 2025 [1] Financial Performance - For the first half of 2025, the company reported revenue of 100 million HKD, representing a year-on-year increase of 92.82% [1] Product Development and Innovation - The company has made substantial progress in research and clinical trials for its core pipeline, achieving commercialization for eight indications across four major types of cognitive disorders [1] - The company is also advancing AI innovations in the medical field, with its self-developed medical large model, BrainAuGPT, receiving a national invention patent for a novel training task combination method based on GBR second-order knowledge expression [1]